Shots:

• The P-III MONARCH 2 study involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 pre/peri- and postmenopausal women in a ratio (2:1) with HR+- HER2- metastatic breast cancer whose cancer progressed following endocrine therapy
• The P-III MONARCH 2 study resulted in meetings 2EP of overall survival with no new observed safety signals. The P-III MONARCH study previously met its 1EPs i.e- improvement in PFS which serves as the basis for its approval in 50+ countries
• Verzenio is a CDK 4 & 6 inhibitors which are activated by binding to D-cyclins- inhibiting Rb phosphorylation with blocking progression from G1 to S phase of the cell cycle resulting in senescence and apoptosis

Click here to­ read full press release/ article

Ref: Eli Lilly | Image: Eli Lilly